文献速递神经免疫

血清GFAP与神经丝轻链作为NMOSD疾病活动度和残疾的生物标志物

Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
PubMed 文献 · Neurology · 2019-08-30

研究检测健康对照49例、NMOSD患者33例和MS患者49例的血清及脑脊液GFAP与NfL水平,发现两者血清与脑脊液强相关,NMOSD患者血清GFAP和NfL均高于健康对照,且复发后sGFAP升高,sGFAP和sNfL与EDSS评分相关,复发时sGFAP/sNfL商可区分NMOSD与MS。

要点

  • NMOSD患者血清GFAP和NfL水平均显著高于健康对照(均p<0.001)。
  • NMOSD患者sGFAP高于MS患者(中位数207.7 vs 121.1 pg/mL,p<0.001)。
  • 复发时sGFAP/sNfL商区分NMOSD与MS的敏感度73.0%、特异度75.8%。

核心结论

  • sGFAP和sNfL可能是NMOSD疾病活动度和残疾的良好生物标志物。
  • 复发时sGFAP/sNfL商是潜在的NMOSD诊断标志物。

研究设计与样本

  • 研究纳入健康对照49例(49份血清样本)、NMOSD患者33例(42份脑脊液和102份血清样本)和MS患者49例(53份脑脊液和91份血清样本)。
  • 采用超灵敏单分子阵列技术检测血清和脑脊液GFAP与NfL水平,并分析其与临床参数的相关性。

主要发现

  • GFAP和NfL的脑脊液与血清水平均强相关。
  • NMOSD患者血清GFAP和NfL均高于健康对照(均p<0.001)。
  • NMOSD患者sGFAP高于MS患者(中位数207.7 vs 121.1 pg/mL,p<0.001)。
  • NMOSD患者近期复发后sGFAP浓度升高(540.9 vs 152.9 pg/mL,p<0.001)。
  • 多变量分析显示sGFAP和sNfL与NMOSD的EDSS评分相关(分别为p=0.026和p<0.001)。

关键数值与推荐

  • 复发时sGFAP/sNfL商区分NMOSD与MS的敏感度为73.0%、特异度为75.8%。

临床怎么用

  • 血清GFAP和NfL可用于评估NMOSD疾病活动度和残疾程度。
  • 复发时检测sGFAP/sNfL商有助于鉴别NMOSD与MS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To test the hypothesis that serum levels of glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL), which are an intermediate astrocyte and neuron filaments, respectively, are clinically useful biomarkers of disease activity and disability in neuromyelitis optica spectrum disorders (NMOSD). METHODS: Levels of GFAP and NfL in serum (sGFAP and sNfL, respectively) and in CSF samples were measured in healthy controls (HCs) (n = 49; 49 serum samples), patients with NMOSD (n = 33; 42 CSF and 102 serum samples), and patients with multiple sclerosis (MS) (n = 49; 53 CSF and 91 serum samples) by ultrasensitive single-molecule array assays. Association of sGFAP and sNfL levels with clinical parameters was determined. RESULTS: For both GFAP and NfL, CSF and serum levels were strongly correlated. Both were higher in the serum of patients with NMOSD than in HCs (both p < 0.001). Moreover, sGFAP was higher in NMOSD than in MS (median 207.7 vs 121.1 pg/mL, p < 0.001). In NMOSD, sGFAP concentration increased after recent relapse (540.9 vs 152.9 pg/mL, p < 0.001). Multivariate analyses indicated that sGFAP and sNfL were associated with Expanded Disability Status Scale score in NMOSD (p = 0.026 and p < 0.001, respectively). Higher sGFAP/sNfL quotient at relapse differentiated NMOSD from MS with a sensitivity of 73.0% and a specificity of 75.8%. CONCLUSIONS: sGFAP and sNfL are likely to be good biomarkers of disease activity and disability, and the sGFAP/sNfL quotient at relapse is a potential diagnostic marker for NMOSD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Watanabe M, Nakamura Y, Michalak Z, et al. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology. 2019. PMID: 31471502. doi:10.1212/WNL.0000000000008160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。